Timothy R. Ramdeen
Timothy R. Ramdeen has nearly a decade of experience in private equity and hedge fund investing, capital markets, and company formation.
Since June 2022, Mr. Ramdeen has been founder and managing partner of Dharma Capital Advisors, an investment and advisory firm focused on early-stage private and public companies. From March 2021 to March 2022, Mr. Ramdeen was co-founder, chief investment officer, and portfolio manager at Sixth Borough Capital Management, a multi-stage, event-driven hedge fund focused on both private and public equities.
Since 2022, Mr. Ramdeen has been the co-founder of Amplexd Therapeutics, which is a women’s health/biotechnology company focused on providing low-cost, effective, safe and accessible treatments for early cervical and HPV-related cancers worldwide. Mr. Ramdeen also serves as a corporate advisor/board member to multiple early-stage companies and investment funds.
Previously, Mr. Ramdeen was the fifth hire at Altium Capital Management (“Altium”), a healthcare-focused investment firm, where from July 2019 to March 2021 he served as the sole investment analyst on the private capital markets/special situations desk (privately-negotiated financings, direct investments, event-driven long/short, and private to public investments in micro and small-cap companies). During his tenure at Altium, Mr. Ramdeen was instrumental in co-creating the firm’s SPAC and reverse merger investment efforts and establishing extensive relationships with sell-side constituents, buy-side counterparts, and hundreds of private and publicly traded companies across biotechnology, therapeutics, healthcare services, medical devices and medtech.
Prior to Altium, from September 2017 to July 2019, Mr. Ramdeen served as the sole investment analyst at Brio Capital Management, a New York-based event-driven/special situations hedge fund focused on small-cap equities, where he invested as a generalist. In addition to spearheading all investments on behalf of the firm, Mr. Ramdeen assumed increasing degrees of responsibility and oversight including general fund/business operations, investor relations, capital raising/business development and compliance. Before entering public markets investing, Prior to 2017, Mr. Ramdeen also spent time in private equity working for both a private New York‑based family office and Focus Financial Partners, a publicly traded holding company.
Mr. Ramdeen received his B.S. in Biology from Temple University, where he conducted scientific research across neurology, oncology, and developmental biology. In addition, Mr. Ramdeen earned his MBA in Finance from NYU Stern School of Business.